In the TGF-Beta pathway, SMAD2 mutations were more frequent in H/L patients, while SMAD4 mutations were more common in NHW patients, indicating potential differences in tumor suppressor pathway disruption. This evidence concerns the gene SMAD2 and neoplasm.